第39届圣安东尼奥乳腺癌研讨会（39th Annual San Antonio Breast Cancer Symposium SABCS 2016）将于12月6-10日在美国-圣安东尼奥举行。本次研讨会旨在向广大学术专家和研究人员提供有关乳腺癌及癌前乳腺疾病的实验生物学、病因学、预防、诊断和治疗的最新信息。预计将有来自90多个国家的7500名人员参会，大会设置教育专场、特别国际会议、职业发展论坛、临床科学论坛、基础科学论坛、病例讨论、海报讨论等专场，其中，口头报告是最精彩也是最值得期待的部分，届时将有乳腺癌领域的专家学者汇报最新研究成果。

 

　　SABCS 2016精彩口头报告

 

　　Oral Session: General Session 1（Wednesday， December 7）

 

　　[S1-03] First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer -09:15 AM

 

　　多中心III期DATA试验比较绝经后激素受体阳性乳腺癌女性2-3年他莫昔芬治疗后应用3年阿那曲唑与应用6年阿那曲唑的初期结果

 

　　[S1-04] Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05) - 09:30 AM

 

　　5年辅助内分泌治疗后延长来曲唑治疗的最佳持续时间的随机化III期IDEAL试验结果（BOOG 2006-05）

 

　　[S1-07] Immune sculpting of the triple negative breast cancer genome - 10:15 AM

 

　　三阴性乳腺癌基因组的免疫雕刻

 

　　[S1-08] Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study - 10:30 AM

 

　　肿瘤浸润淋巴细胞（TIL）在曲妥珠单抗联合帕妥珠单抗治疗的转移性HER2阳性乳腺癌中的预后相关性CLEOPATRA研究的二次分析研究

 

　　[S1-09] Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients - 10:45 AM

 

　　肿瘤浸润淋巴细胞（TILs）作为预后和预后生物标志物在新辅助治疗不同亚型乳腺癌中的 3771例患者的荟萃分析

 

　　[S1-10] Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study - 11:00 AM

 

　　体细胞突变在绝经后早期雌激素受体阳性HER2阴性乳腺癌中的临床意义：BIG 1-98研究结果

 

　　Oral Session: General Session 2（Wednesday， December 7）

 

　　[S2-01] Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60，000 breast cancer patients - 03:15 PM

 

　　一项60，000乳腺癌患者的临床基因检测确定的乳腺癌风险相关癌症易感基因突变的研究

 

　　[S2-02] The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers - 03:30 PM

 

　　BRCA1和BRCA2乳腺癌体细胞表观遗传改变

 

　　[S2-03] Does BRCA status affect outcome in young breast cancer patients？Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH) - 03:45 PM

 

　　BRCA状态会影响年轻乳腺癌患者的结局吗？ 来自散发性和遗传性乳腺癌的前瞻性研究结果

 

　　[S2-04] RANK ligand as a target for breast cancer prevention in BRCA1mutation carriers - 04:00 PM

 

　　RANK配体作为BRCA1突变携带者乳腺癌预防的靶向目标

 

　　[S2-06] DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer - 04:30 PM

 

　　来自针对高危乳腺癌的新辅助I-SPY 2试验的结果：DNA修复缺陷生物标志物和MammaPrint high1 /（超）高2风险作为veliparib /卡铂应答的预测因子

 

　　Oral Session: General Session 3（Wednesday， December 8）

 

　　[S3-01] IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy - 09:30 AM

 

　　IMENEO：新辅助化疗治疗的早期乳腺癌患者循环肿瘤细胞检测的国际META分析

 

　　[S3-02] Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO - 09:45 AM

 

　　来自Neo-ALTTO研究的结果：血浆微RNA水平用于预测HER2阳性乳腺癌对新辅助治疗的反应

 

　　[S3-03] PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial - 10:00 AM

 

　　PAMELA临床试验的首次结果：PAM50内在亚型作为未化疗的HER2阳性乳腺癌新辅助双重HER2阻断后病理学完全缓解的预测因子

 

　　[S3-04] Primary analysis of PERTAIN: A randomized， two-arm， open-label， multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer - 10:15 AM

 

　　PERTAIN的主要分析：一项随机，双臂，开放性的多中心II期试验，评估帕妥珠单抗在给予曲妥单抗联合芳香酶抑制剂的HER2阳性和激素受体阳性转移性或局部晚期乳腺癌患者一线治疗中的疗效和安全性

 

　　[S3-05] Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance)， a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer - 10:30 AM

 

　　CALGB 40601（Alliance）多维基因组数据的综合分析，每周紫杉醇和曲妥珠单抗联合或不联合拉帕替尼治疗HER2-阳性乳腺癌的随机，新辅助III期试验

 

　　[S3-08] Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial - 11:15 AM

 

　　丹麦的多中心随机对照试验：在非肿块性浸润性原位乳腺癌中放射性种子定位与导丝引导定位的对比

 

　　Oral Session: General Session 4 （Wednesday， December 8）

 

　　[S4-01] A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models - 03:15 PM

 

　　一种新型BRD4抑制剂增强雌激素受体阳性乳腺癌患者的内分泌治疗效果和规避内分泌耐药

 

　　[S4-02] The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis - 03:30 PM

 

　　Y537S ESR1突变是ER阳性乳腺癌远处转移的主要驱动因素

 

　　[S4-03] Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs - 03:45 PM

 

　　通过PROTACs 雌激素受体α的靶向和选择性降解

 

　　[S4-04] Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive， HER2-negative early stage breast cancer (ESBC) - 04:00 PM

 

　　转移性肿瘤微环境评分与激素受体阳性，HER2阴性早期乳腺癌的早期远处复发相关

 

　　[S4-05] Expression of the DEK oncogene promotes M2 polarization and iron recycling in tumor associated macrophages - 04:15 PM

 

　　DEK癌基因的表达促进M2极化和肿瘤相关的巨噬细胞中铁的吸收

 

　　Oral Session: General Session 5（Wednesday， December 9）

 

　　[S5-01] DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population - 09:30 AM Kaiser Permanente NW

 

　　人群保乳手术后复发风险的DCIS生物风险概况预测

 

　　[S5-04] Low-fat dietary pattern and breast cancer overall survival in the women’s health initiative dietary modification randomized controlled trial - 10:15 AM

 

　　一项针对低脂肪饮食模式和乳腺癌的总生存的妇女健康倡议膳食修改的随机对照试验

 

　　[S5-05] Impact of pre-operative exercise on breast cancer gene expression - 10:30 AM

 

　　术前运动对乳腺癌基因表达的影响

 

　　[S5-06] Randomized， placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202) - 10:45 AM

 

　　一项针对早期乳腺癌中芳香酶抑制剂相关肌肉骨骼症状的度洛西汀的随机，安慰剂对照试验（SWOG S1202）

 

　　Oral Session: General Session 6 （Wednesday， December 9）

 

　　[S6-01]BRCA1methylation status， silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) - 03:15

 

　　PMTNT试验中BRCA1甲基化状态，沉默和治疗效果：一项针对转移性或复发性局部晚期三阴性或BRCA1 / 2乳腺癌患者（CRUK / 07/012）的卡铂对比多西紫杉醇的随机III期试验

 

　　[S6-03] DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer - 03:45 PM

 

　　DBCG 07-READ：一项对早期乳腺癌患者进行三个周期的多西他赛治疗后，对比多西紫杉醇和环磷酰胺六个周期与表柔比星和环磷酰胺三个周期的随机III期临床试验

 

　　[S6-04] The PI3K inhibitor， taselisib， has enhanced potency in PIK3CA mutant models through a unique mechanism of action - 04:00 PM

 

　　在PIK3CA突变模型中PI3K抑制剂taselisib通过独特的作用机制增强效力

 

　　[S6-05] Comprehensive comparison of prognostic signatures for breast cancer in TransATAC - 04:15 PM

 

　　TransATAC中综合比较乳腺癌的预后签名